Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Potential of adjuvant therapy for RCC

Matthew Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the implications of the 30-month follow-up of the KEYNOTE-564 trial (NCT03142334), which investigated adjuvant pembrolizumab post-nephrectomy in patients with renal cell carcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.